VIENNALAB - Established innovations in diagnostics

Alpha-1 Antitrypsin (AAT) deficiency is an inherited disorder and still an underrecognized, but treatable cause of chronic obstructive pulmonary disease (COPD). The AAT RealFast™ Assay is designed for simultaneous detection of the protease inhibitor (PI) variants *S and *Z of the SERPINA1 gene representing the most frequent alleles associated with AAT deficiency.

Consequences of AAT deficiency

  • Unhindered proteolysis in the lungs, due to low serum levels of protease inhibitor AAT, causes damage of alveolar tissue and development of chronic obstructive pulmonary disease (i.e. emphysema, persistent airflow obstruction, and/or chronic bronchitis).
  • Genetic testing helps to diagnose AAT deficiency as the cause of early onset emphysema, bronchiectasis, unexplained liver disease, or necrotizing panniculitis.
  • Individuals carrying the PI*ZZ genotype are at a high risk of developing emphysema and liver disease, whereas PI*SZ carriers have lower risk. PI*MM, *MS or *SS genotypes have normal or only slightly decreased AAT plasma levels.

Product Details

AAT RealFast™ Assay ref7-265 7-268